Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NRX PharmaceuticalsFRA:B1Q +5.42%33 EBITDA Margin % is -96.65% as of Mar. 2026. GuruFocus rates FRA:B1Q with a GF Score™ of 33/100. The stock has 4 warning signs investors should review. Among 940 Biotechnology companies, NRX Pharmaceuticals ranks worse than 79.36% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. NRX Pharmaceuticals's EBITDA for the
three
months ended in Mar. 2026 was €-0.89 Mil. NRX Pharmaceuticals's Revenue for the
three
months ended in Mar. 2026 was €0.92 Mil. Therefore, NRX Pharmaceuticals's EBITDA margin for the quarter that ended in Mar. 2026 was -96.65%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
NRX Pharmaceuticals EBITDA Margin % Related Terms
NRX Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for NRX Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:B1Q vs CRBP, PRQR, TNYA: EBITDA Margin % Comparison
For the Biotechnology subindustry, NRX Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NRX Pharmaceuticals EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NRX Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where NRX Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NRX Pharmaceuticals (FRA:B1Q) has a EBITDA Margin % of -96.65% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on NRX Pharmaceuticals and its competitors. According to the industry distribution chart, NRX Pharmaceuticals ranks #746 out of 940 companies in the Biotechnology industry, placing it in the top 79.4%.
Is NRX Pharmaceuticals' EBITDA Margin % too high?
NRX Pharmaceuticals' current EBITDA Margin % is -96.65%. Based on the distribution chart, NRX Pharmaceuticals ranks #746 out of 940 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NRX Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does NRX Pharmaceuticals' EBITDA Margin % compare to CRBP and PRQR?
According to the Biotechnology industry distribution chart, NRX Pharmaceuticals ranks #746 out of 940 companies for EBITDA Margin %. This places NRX Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on NRX Pharmaceuticals and its competitors. NRX Pharmaceuticals's current EBITDA Margin % is -96.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NRX Pharmaceuticals stock overvalued right now?
NRX Pharmaceuticals (FRA:B1Q) has a current EBITDA Margin % of -96.65%. The current EBITDA Margin % is -96.65%. NRX Pharmaceuticals' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For NRX Pharmaceuticals (FRA:B1Q), the current EBITDA Margin % is -96.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
33GF Score
Get the complete analysis for FRA:B1Q
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:B1Q has been successfully added to your 
